Regorafenib plus PD-1 inhibitors in Chinese patients with microsatellite stable/mismatch repair proficient metastatic colorectal cancer: A real-world study.

被引：1
|
作者：
Yang, Kaili
Han, Lu
Zhao, Yun-Bo
Ge, Yang
Li, Qin
Wang, Yusheng
Wu, Shikai
Zhang, Yan
Zhao, Chuanhua
Zhou, Jing
Zhao, Lin
机构：
[1] Peking Union Med Coll Hosp, Beijing, Peoples R China
[2] Chinese PLA Gen Hosp, Dept Med Oncol, Beijing, Peoples R China
[3] Beijing Hosp, Beijing, Peoples R China
[4] Capital Med Univ, Beijing Chaoyang Hosp, Beijing, Peoples R China
[5] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China
[6] Shanxi Med Univ, Affiliated Canc Hosp, Shanxi Canc Hosp, Taiyuan, Peoples R China
[7] Hosp Acad Mil Med Sci, Beijing, Peoples R China
[8] Capital Med Univ, Xuanwu Hosp, Beijing, Peoples R China
[9] 307 Hosp PLA, Beijing, Peoples R China
[10] Peking Univ, Peoples Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e15585
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15585
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer
    Sun, Liying
    Huang, Shenglan
    Li, Dan
    Mao, Ye
    Wang, Yurou
    Wu, Jianbing
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [2] Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study
    Jiang, Feng-E
    Zhang, Hui-Juan
    Yu, Cai-Yan
    Liu, Ai-Na
    NEOPLASMA, 2021, 68 (04) : 861 - 866
  • [3] Regorafenib Combined With PD-1 Inhibition as Salvage Treatment and in a Real-World Study of Patients with Metastatic Colorectal Cancer
    Bekaii-Saab, Tanios S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (09) : 7 - 7
  • [4] Single-Arm, Phase 2 Study of Regorafenib Plus Nivolumab in Patients With Mismatch Repair Proficient/Microsatellite Stable Colorectal Cancer
    Bekaii-Saab, Tanios S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (09) : 3 - 5
  • [5] Regorafenib plus tislelizumab for patients with metastatic colorectal cancer: A real-world study
    Gao, Xiang
    Chen, Xiaoping
    Zhao, Yutian
    Mao, Yong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer
    Telli, Tugba Akin
    Bregni, Giacomo
    Vanhooren, Michele
    Conde, Rita Saude
    Hendlisz, Alain
    Sclafani, Francesco
    CANCER TREATMENT REVIEWS, 2022, 110
  • [7] Fruquintinib Combined With PD-1 Inhibitors for the Treatment of the Patients With Microsatellite Stability Metastatic Colorectal Cancer: Real-World Data
    He, L.
    Cheng, X.
    Gu, Y.
    Zhou, C.
    Li, Q.
    Zhang, B.
    Cheng, X.
    Tu, S.
    CLINICAL ONCOLOGY, 2025, 38
  • [8] Anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer: A retrospective study.
    Li, Rongrong
    Liu, Zhenyang
    Yin, Xianli
    Zeng, Deyu
    Jiang, Shaofeng
    Wu, Liu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15582 - E15582
  • [9] Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study
    Kaili Yang
    Lu Han
    Shikai Wu
    Xiujuan Qu
    Qin Li
    Chuanhua Zhao
    Jing Zhou
    Xuan Jin
    Yusheng Wang
    Dong Yan
    Zhiqiang Cheng
    Yuwei Hua
    Yan Zhang
    Yang Ge
    Jinghua Sun
    Wei Deng
    Lin Zhao
    Yunbo Zhao
    Cancer Immunology, Immunotherapy, 2022, 71 : 1443 - 1451
  • [10] Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study
    Yang, Kaili
    Han, Lu
    Wu, Shikai
    Qu, Xiujuan
    Li, Qin
    Zhao, Chuanhua
    Zhou, Jing
    Jin, Xuan
    Wang, Yusheng
    Yan, Dong
    Cheng, Zhiqiang
    Hua, Yuwei
    Zhang, Yan
    Ge, Yang
    Sun, Jinghua
    Deng, Wei
    Zhao, Lin
    Zhao, Yunbo
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (06) : 1443 - 1451
12345